HNRNPA2B1, Human (GST)

MEREKEQFRKLFIGGLSFETTEESLRNYYEQWGKLTDCVVMRDPASKRSRGFGFVTFSSMAEVDAAMAARPHSIDGRVVEPKRAVAREESGKPGAHVTVKKLFVGGIKEDTEEHHLRDYFEEYGKIDTIEIITDRQSGKKRGFGFVTFDDHDPVDKIVLQKYHTINGHNAEVRKALSRQEMQEDLEVAILEVAPVMEEEEEDMVVEDLDMATRVGATEVVMTTMEEEIMEVEITMILEIITSNLLTTVQ

[1]Huang Y, et al. A2/B1 Promotes NRF2 mRNA Stability and Inhibits Ferroptosis and Cell Proliferation in Breast Cancer Cells. Biomed Res Int. 2023 Apr 14;2023:2620738.|[2]Ruffenach G, et al. HNRNPA2B1: RNA-Binding Protein That Orchestrates Smooth Muscle Cell Phenotype in Pulmonary Arterial Hypertension. Circulation. 2022 Oct 18;146 (16) :1243-1258.|[3]Chen C, et al. HNRNPA2B1 Demonstrates Diagnostic and Prognostic Values Based on Pan-Cancer Analyses. Comput Math Methods Med. 2022 Apr 27;2022:9867660.|[4]Kim HJ, et al. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat Commun. 2022 Apr 28;13 (1) :2306.|[5]Petri BJ, et al. HNRNPA2B1 regulates tamoxifen- and fulvestrant-sensitivity and hallmarks of endocrine resistance in breast cancer cells. Cancer Lett. 2021 Oct 10;518:152-168.